Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction

Journal of the American College of Cardiology

Volumn 44, Issue 10, 2004, Pages 1970-1976

  Ueland, Thor ^a,b,d   Jemtland, Rune ^b   Godang, Kristin ^b   Kjekshus, John ^c   Hognestad, Aina ^a,e   Omland, Torbjørn ^f   Squire, Iain B ^h   Gullestad, Lars ^e   Bollerslev, Jens ^b   Dickstein, Kenneth ^g   Aukrust, Pål ^a,d  

^a Research Institute for Internal Medicine   (Norway)

^b Section of Endocrinology   (Norway)

^c Department of Cardiology ^*

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e VESTRE VIKEN HOSPITAL TRUST   (Norway)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF BERGEN   (Norway)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HORMONE; LOSARTAN; OSTEOPROTEGERIN; VASODILATOR AGENT;

ACUTE HEART INFARCTION; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; FOLLOW UP; HEART FAILURE; HUMAN; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

AGED; CASE-CONTROL STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 8144227919     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.06.076     Document Type: Article

References (29)

1. R. Vliegenthart, M. Oudkerk, B. Song, D.A. van der Kuip, A. Hofman, J.C. Witteman Coronary calcification detected by electron-beam computed tomography and myocardial infarction: the Rotterdam Coronary Calcification study Eur Heart J 23 2002 1596 1603
2. J.R. Margolis, J.T. Chen, Y. Kong, R.H. Peter, V.S. Behar, J.A. Kisslo The diagnostic and prognostic significance of coronary artery calcification: a report of 800 cases Radiology 137 1980 609 616
3. C.R. Dhore, J.P. Cleutjens, E Lutgens Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques Arterioscler Thromb Vasc Biol 21 2001 1998 2003
4. A.P. Gadeau, H. Chaulet, D. Daret, M. Kockx, J.M. Daniel-Lamaziere, C. Desgranges Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury J Histochem Cytochem 49 2001 79 86
5. K.L. Tyson, J.L. Reynolds, R. McNair, Q. Zhang, P.L. Weissberg, C.M. Shanahan Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification Arterioscler Thromb Vasc Biol 23 2003 489 494
6. L.A. Fitzpatrick, R.T. Turner, E.R. Ritman Endochondral bone formation in the heart: a possible mechanism of coronary calcification Endocrinology 144 2003 2214 2219
7. M. Schoppet, K.T. Preissner, L.C. Hofbauer RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function Arterioscler Thromb Vasc Biol 22 2002 549 553
8. K. Nitta, T. Akiba, K Uchida The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis Am J Kidney Dis 42 2003 303 309
9. M. Haas, Z. Leko-Mohr, P Roschger Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients Am J Kidney Dis 39 2002 580 586
10. M. Schoppet, A.M. Sattler, J.R. Schaefer, M. Herzum, B. Maisch, L.C. Hofbauer Increased osteoprotegerin serum levels in men with coronary artery disease J Clin Endocrinol Metab 88 2003 1024 1028
11. S. Jono, Y. Ikari, A Shioi Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease Circulation 106 2002 1192 1194
12. W.S. Browner, L.Y. Lui, S.R. Cummings Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women J Clin Endocrinol Metab 86 2001 631 637
13. S. Kiechl, G. Schett, G Wenning Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease Circulation 109 2004 2175 2180
14. K. Dickstein, J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 360 2002 752 760
15. T. Ueland, J. Bollerslev, K. Godang, F. Muller, S.S. Froland, P. Aukrust Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis Eur J Endocrinol 145 2001 685 690
16. T. Omland, A. Persson, L Ng N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes Circulation 106 2002 2913 2918
17. E. Terpos, R. Szydlo, J.F Apperley Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index Blood 102 2003 1064 1069
18. W.S. Simonet, D.L. Lacey, C.R Dunstan Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319
19. L.C. Hofbauer, C. Shui, B.L Riggs Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells Biochem Biophys Res Commun 280 2001 334 339
20. U.M. Malyankar, M. Scatena, K.L. Suchland, T.J. Yun, E.A. Clark, C.M. Giachelli Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells J Biol Chem 275 2000 20959 20962
21. T.J. Yun, P.M. Chaudhary, G.L Shu OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40 J Immunol 161 1998 6113 6121
22. H. Brandstrom, K.B. Jonsson, O. Vidal, S. Ljunghall, C. Ohlsson, O. Ljunggren Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells Biochem Biophys Res Commun 248 1998 454 457
23. A. Deten, H.C. Volz, W. Briest, H.G. Zimmer Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction: experimental studies in rats Cardiovasc Res 55 2002 329 340
24. L. Kritharides, G.T. Lau, B. Freedman Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348 2003 2575 2577
25. R. Latini, M. Bianchi, E Correale Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist J Cardiovasc Pharmacol 23 1994 1 6
26. P. Aukrust, F. Muller, T Ueland Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes Circulation 100 1999 614 620
27. K. Yano, E. Tsuda, N Washida Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis J Bone Miner Res 14 1999 518 527
28. J.G. Emery, P. McDonnell, M.B Burke Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 1998 14363 14367
29. J. Zhang, M. Fu, D Myles PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways FEBS Lett 521 2002 180 184